Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

Reumatismo. 2016 Dec 16;68(3):163-165. doi: 10.4081/reumatismo.2016.911.

Abstract

We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antirheumatic Agents / therapeutic use*
  • Biomarkers / blood
  • Discitis / blood
  • Discitis / diagnosis*
  • Discitis / drug therapy*
  • Discitis / immunology
  • Etanercept / therapeutic use*
  • Fluorodeoxyglucose F18 / pharmacokinetics
  • HLA-B27 Antigen / blood*
  • Humans
  • Lumbar Vertebrae / diagnostic imaging*
  • Male
  • Positron Emission Tomography Computed Tomography* / methods
  • Radiopharmaceuticals / pharmacokinetics
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Biomarkers
  • HLA-B27 Antigen
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Etanercept